Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides

Bioseeker, January 2013, Pages: 3376

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Cancer Vaccines
The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

- Supporting development of integrative molecule, pathway and disease area strategies

- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of
Pages: 1,704

Part II: Cancer Vaccines
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets) 30-194
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs) 195-308
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 309-338
9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications) 339-386
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators) 387-649
11 Disclaimer 650
12 Drug Index 651
13 Company Index 656
Figures: Includes 6 Figures
Tables: Includes 205 Tables
Total Number of
Pages: 659

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of
Pages: 1,013

Customers who bought this item also bought

• Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market
• Personalized Medicine - Scientific and Commercial Aspects
• Antibody Drug Target Atlas in Oncology
• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
• Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
• Transdermal Drug Delivery - Technologies, Markets, and Companies
• Global Oncology Drug Pipeline Capsule – 2012
• Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
• Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance